Based out of Delhi, Redcliffe offers services including clinical exome sequencing, NIPS, and cancer large gene panel tests that are non-invasive and harmless for the foetus. Its range of diagnostics includes fertility tests, reproductive tests, screening of foetus and embryos for Down Syndrome, cancer liquid biopsies, and diagnosing rare diseases in the first trimester of pregnancy. Having founded the company in 2018, Redcliffe first built its centralised lab and then started with the various clinical validations of its tests, using CAP guidelines. Subsequently, it entered the market with its commercial offerings in 2019. Over the last year, it has already processed over 5,000 samples at its lab. Its clients include Dr Lal Pathlabs, and hospitals and institutes including PGI Chandigarh, AIIMS, Sir Ganga Ram in New Delhi, Bharti Vidhya Peeth Pune, among others. Redcliffe is also an exclusive partner of Ambry Genetics. Redcliffe charges a service fee for each of the tests it conducts, like any other diagnostic company.
Something About Company
